U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Guideline Alliance (UK). Cystic Fibrosis: Diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)

Cover of Cystic Fibrosis

Cystic Fibrosis: Diagnosis and management.

Show details

Table 125Comparison 2 SA results

TreatmentTotal costsTotal QALYsICER
FEV1% utility
Nebulised colistimethate sodium£107,14912.99-
Nebulised tobramycin£244,89013.10£1,226,546
Tinnitus excluded
Nebulised colistimethate sodium£125,00211.35-
Nebulised tobramycin£205,66411.54£416,476
Within-trial analysis
Nebulised colistimethate sodium£4,4210.42-
Nebulised tobramycin£8,4170.42£1,524,290
Hodson 2002 (FEV1%)
Nebulised colistimethate sodium£107,14911.35-
Nebulised tobramycin£245,23911.48£1,023,402
Hodson 2002 (cost)
Nebulised colistimethate sodium£107,14911.35-
Nebulised tobramycin£308,80411.58£882,028
Nebulised colistimethate sodium cost
Nebulised colistimethate sodium£147,74811.35-
Nebulised tobramycin£244,89011.58£424,896
Nebulised tobramycin drug cost
Nebulised colistimethate sodium£107,14911.35-
Nebulised tobramycin£251,41611.58£631,016
Nebulised colistimethate sodium dose
Nebulised colistimethate sodium£125,00211.35-
Nebulised tobramycin£244,89011.58£524,384
WinBUGS
Nebulised colistimethate sodium£107,56811.34
Nebulised tobramycin£245,30611.57£602,328
PAS
Nebulised colistimethate sodiumNo change11.35-
Nebulised tobramycinReduced11.58Reduced (>£30,000)

FEV, forced expiratory volume; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; PAS, patient access scheme; SA, sensitivity analysis

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...